Home News Drug Discovery & Development

Drug Discovery & Development

The Illustrated Guide to Living with Diabetes in India, a Self-management Guide for Diabetics...

Mumbai, Maharashtra, India, Monday, April 22, 2013 -- (Business Wire India) -- 'The Illustrated Guide to Living with Diabetes in India', a practical guide to self-manage diabetes was launched at Kochi on Friday, April 19, 2013 by Sir Michael Hirst, President, International Diabetes Federation (IDF) during the 5 th World Congress of DiabetesIndia. Dr. Shaukat Sadikot, President - Elect, IDF and Prof. Dr. Jean Claude Mbanya, Past-President, IDF was also present during this occasion. The book authored by The Living with Diabetes in India (LWDI), an online community for people with diabetes with over half a million members - and co-published in India by Popular Prakashan, is now available at leading book stores across India and through online retailers.

Glenmark study on novel antibody

MUMBAI, AUGUST 21, 2014: Drugmaker Glenmark Pharmaceuticals is set to initiate studies on its novel drug candidate, GBR 1302, an antibody with dual specificities. Explaining the significance of the discovery, Michael Buschle, Glenmark’s Chief Scientific Officer and President (Biologics) said...

Drug Discovery Unit (DDU), University of Dundee Licenses GVK BIO Online SAR Database (GOSTAR)

Hyderabad, Andhra Pradesh, India, Wednesday, April 10, 2013 -- (Business Wire India) -- GVK Biosciences (GVK BIO) today announced that it has licensed its Online SAR Database - GOSTAR to the Drug Discovery Unit (DDU) at the University of Dundee. GOSTAR, a manually curated database, has been developed over the span of a decade by a team comprising of more than 200 curators. The product issued globally in various areas such as pharmaceuticals, academics, government sectors, apart from numerous publications that cite the data contained in GOSTAR. GOSTAR contains over 6 million compounds manually curated through the screening of over 2 million patents and 400,000 journals and it also contains more than 18 million quantitative SAR points.

Venus Remedies ties up with Israel’s Teva for anti-cancer drug

Chandigarh, August 27, 2014 -  Pharma major Venus Remedies today said it has entered into a collaborative agreement with Israel-based generic drug maker Teva for selling an anti- cancer drug in the Canadian market. Under this collaboration, Venus Remedies will be initially manufacturing the...

Venus Remedies gets Swiss nod to market oncology drug

Chandigarh, august 21, 2014 - Pharma major Venus Remedies has secured its first marketing authorisation in Switzerland from Swiss drug authority ‘Swissmedic’ for its oncology drug ’Gemcitabine’ The marketing approval for Gemcitabine will help the company further strengthen its oncology...

‘New drug for Alzheimer’s, Parkinson’s in the pipeline’

New Delhi December 28, 2013: The Government’s drug price control order may have impacted drug-makers’ profitability, but Chennai-based Arvind Remedies Ltd is unfazed. A new drug to combat Alzheimer’s and Parkinson’s diseases is in the pipeline, says B. Arvind...

Bharat Biotech and University of Maryland Accelerate Development of New Life Saving Conjugate Vaccine...

Receive USD 4 Million Award from The Wellcome Trust for Development and Clinical Trials Hyderabad, India, June 18, 2012: Bharat Biotech and The University of Maryland Center for  Vaccine Development (“CVD”) announced today a significant milestone achievement– receiving a USD  4 Million Strategic Translation Award from The Wellcome Trust for clinical development of a new  conjugate vaccine including initial clinical trials beginning in three years to prevent the potentially  lethal infectious disease caused by invasive non-typhoidal Salmonella (NTS).   NTS have emerged as an important cause of invasive bloodstream infection in sub-Saharan Africa,  among young children with malaria and malnutrition, and among adults with HIV. Strains of nontyphoidal Salmonella (“NTS”) that can cause systemic disease such as meningitis or sepsis are  particularly common in sub-Saharan Africa; approximately 20 to 30% of children with such invasive  NTS infections die.

Cadila Healthcare divests its entire stake in Bremer Pharma, Germany

Mumbai, April 20, 2018: Cadila Healthcare said that company has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a wholly owned subsidiary of the company and consequently, Bremer ceased to be a subsidiary of the company. The company received...

New potential breast cancer drug identified

New Delhi, April 20,  2018: Scientists, including an Indian-American researcher, have identified a molecule that can help treat breast cancer, giving hope to patients who have become resistant to traditional therapies. The first-in-class molecule shuts down oestrogen-sensitive breast cancer in...

Cipla bets big on cell therapy

Mumbai , March 22,2014 - Stem cells are set to be a major branch of medical treatment, says Cipla Chairman YK Hamied. Regenerative medicine, or cell therapy, is a rapidly emerging area of biomedical research and would be...